First-line durvalumab therapy alone or in combination with tremelimumab for metastatic head and neck squamous cell carcinoma: A cost-effectiveness analysis - Huijuan Li; Xueyan Liang; Shiran Qin; Xiaoyu Chen; Liju Huang; Yan Li (PLoS ONE, 2025)